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Abstract: 
The purpose of this study was to determine the mechanism of uptake and release of 
doxorubicin from HA nanoparticle. We used human head and neck squamous cell carcinoma 
MDA-1986 as a model cell line. MDA-1986 was imaged after incubation with HA-DOX (NPs), 
doxorubicin, HA-CY7 or HA-DOX-CY7 at 15 minutes, 1, 6, 24, and 48 hours’ time points using 
an inverted fluorescence microscope. Also, the cell nucleus was stained with DAPI stain, and 
the cells were imaged after incubation with HA-DOX conjugates, doxorubicin, HA-CY7 or HA-
DOX-CY7 for 6 hours. Furthermore, the lysosomes were stained to determine if the lysosomal 
pathway is the major degradation pathway of the nanoparticles and the carrier. To determine 
the internalization mechanism, four inhibition conditions were used: excess HA to block HA 
receptors, anti CD44 antibody (Hermes-1) to block the CD44 receptor, chlorpromazine to inhibit 
clathrin mediated endocytosis, and reduced temperature of 4°C. The fluorescence intensities of 
the cells co-incubated with the nanoparticle or the carrier with different inhibitors were compared 
using the inverted fluorescence microscope. The quantitative analysis of cells treated with HA-
DOX and co-incubated with different inhibition conditions (10 mg/mL HA, chlorpromazine, 
Hermes-1 and 4°C) showed significant decrease in the fluorescence intensity except in cells 
pretreated with 5 mg/mL HA. Also, the quantitative analysis of cells treated with HA-CY7 and 
co-incubated with different inhibition conditions (excess HA, chlorpromazine and Hermes-1) 
showed significant decrease in the fluorescence intensity. However, the quantitative analysis of 
cells treated with free doxorubicin or HA-DOX-CY7 showed significant decrease in the 
fluorescence intensity in only cells pretreated with 25- µM chlorpromazine or cells incubated at 4 
°C. The suggested internalization mechanism of HA-DOX conjugates is an active transport 
mechanism mediated mainly by the CD44, one of the HA receptors, through a clathrin-
dependent endocytic pathway. On the other hand, a sulfated-HA derivative has similar uptake 
profile as the parent HA-CY7, and it is mainly localized in the cytosol. 
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Chapter 1:  Introduction 
 
1.1 Cellular Drug Uptake: 
 
There are many mechanisms of cellular drug uptake such as passive diffusion, carrier 
mediated transport, and pore transport. Small and lipophilic drugs usually pass the epithelial cell 
membrane by passive diffusion. The driving force for the passive diffusion is the concentration 
gradient. On the other hand, carrier-mediated transport utilizes specialized proteins to transport 
molecules. The specialized membrane proteins may pass the drug to the intracellular 
compartment by active transport, which is against the concentration gradient, or by facilitated 
diffusion, which is with the concentration gradient. Active transport is an energy consuming 
process because it is against the concentration gradient.  
Endocytosis or engulfment of extracellular materials can be a major transport 
mechanism of large molecules that are more than 500 Da. It can be divided into two types; 
pinocytosis and phagocytosis.  Pinocytosis is the invagination and formation of an inward 
channel, and it is a non-specific process. However, phagocytosis is a specific process for some 
specialized cells known as reticuloendothelial cells.  On the other hand, very small hydrophilic 
molecules such as water can pass through the small pores in the cell membrane. These small 
pores are approximately 0.4 nm in diameter, but most drug molecules are larger than 1 nm in 
diameter. So, there is more than one mechanism for drugs or molecules to transport inside the 
cells. Some of them require energy and the mechanism of transport depend on size, molecular 
weight and solubility of the drug (1). 
1.2 Nanoparticles and drug uptake: 
 
Nanoparticles are complex systems with a nanometer scale from 10 to 100 nm, 
consisting of an active ingredient, such as drug or biomarker, and a carrier. This complex 
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system can be utilized for therapy, diagnosis or both as a theragnostic. The goals of using 
nanotechnology in the drug delivery are: increase in specificity, reduction in toxicity, and quicker 
development of a safe and efficacious formulation. However, there are many challenges in the 
fields of drug delivery and nanotechnology to design and produce a new active formulation. 
Some of these challenges are drug release and encapsulation, physical and chemical stability, 
distribution and targeting of the drug, and in vivo activity. So, the formulator should have broad 
physical, chemical and biological knowledge to succeed in developing a new formulation (2). 
The fate of nanoparticles inside the cells is important. Degradation of the particles after 
intracellular uptake generally occurs in endosomes or lysosomes (2). The encapsulated drug 
inside the nanoparticles should reach the cytosol or the site of action inside the cells to be 
active. Nanoparticles with a particle size of about 20 nm could be taken up by cells without 
contribution of the endocytosis process (6). Surface charge of nanoparticles may have a 
contribution in the localization of the nanoparticles in the cells. For example, gold nanoparticles 
with a pegylated surface can be efficiently internalized in the cytosol and finally localized in the 
nucleus (7). Also, escape from endosomes to the cellular cytoplasm was found with PLGA 
nanoparticles. In contrast, polystyrene nanoparticles remained in the endosomal compartment 
and did not reach the cytosol. The hypothesis was that escape of PLGA nanoparticles from 
endosomes to the cytosol was due to the change in the surface charge from negative to positive 
in the PLGA nanoparticles. The PLGA NPs contained serum albumin, so they acquire a positive 
charge in the acidic pH such as endo-lysosomal vesicles (pH 4). Meanwhile they have a 
negative charge in physiological and alkaline pH, in contrast to polystyrene NPs which have a 
negative charge in all pH values. So, understanding the mechanism of cellular uptake and the 
fate of transport drugs inside the cell can improve the delivery and targeting of the drugs (8, 9). 
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1.3 Role of HA to improve drug uptake in cancers: 
 
Hyaluronan (HA) is an anionic glycosaminoglycan widely distributed throughout the 
body. It is a biodegradable and biocompatible molecule with a wide molecular weight range from 
10 to 10,000 kDa. In tissues, hyaluronan contributes in cell proliferation and migration, and it 
may be involved in cancer metastasis. There are different types of cell receptors of HA, 
including CD44, RHAMM and ICAM-1 receptors. The main cell surface receptor of HA is CD44. 
CD44 receptors mediate cell interaction with HA, and the binding of the two functions as an 
important part in various physiological events such as cell aggregation, proliferation, migration 
and endocytosis of HA which may cause degradation of HA(4). On the other hand, ICAM-1 
receptors function as metabolic cell receptors for HA. When HA binds to these receptors, a 
cascade of events happen including endocytosis of HA which forms early endosomes, then 
fusion of these endosomes with the cellular lysosomes which contain enzymes that degrade the 
HA(4). 
Hyaluronan has some intrinsic properties that make it a good delivery carrier for 
anticancer drugs. Hyaluronan is an endogenous compound and non-immunogenic at molecular 
weights above 10 kDa. Hyaluronan can form a large network at low concentration to entrap 
small anticancer drugs. In a tumor environment, there is overexpression of the CD44 receptor in 
tissues, which facilitates the uptake of the HA-anticancer conjugates by cancer cells. HA-
anticancer conjugates can rapidly enter the tumor and accumulate within the tumor and could 
form an intra-tumoral drug depot after accumulation. So, using HA as a drug delivery carrier 
offers many advantages over other drug carrier systems for targeting cancer cells.  
1.4 HA-doxorubicin conjugates: 
 
Doxorubicin (DOX) is an anticancer drug used for treatment of various forms of cancer, 
including breast and ovarian cancers, sarcomas, pediatric solid tumors, Hodgkin's and non-
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Hodgkin's lymphomas and multiple myeloma. Doxorubicin has several serious side effects, such 
as cardiac toxicity, which may limit its use. To decrease the side effects and toxicity of 
doxorubicin, different technologies can be used to reduce nonspecific tissue toxicity, such as 
polymeric micelles, antibody targeted carriers and polymeric conjugates (10, 17). Several HA–
DOX conjugates have been reported that used peptide linkers, which had a considerable loss of 
anticancer activity (14-16). Our lab synthesized a new pH-sensitive, reversible hydrazone HA–
DOX conjugate with potent anticancer activity against breast cancer cells in vitro and excellent 
cellular uptake and retention (10). 
1.5 Purpose of the study: 
 
The purpose of this study is to observe the effect of HA on DOX uptake after conjugation 
of DOX with HA. Furthermore, to determine which internalization mechanism is used by MDA- 
1986 cell line to uptake the HA-DOX nanoparticles, and the localization of both doxorubicin and 
HA by inverted fluorescence microscope. Also, we investigated and compared the uptake of a 
sulfated form of HA to the parent HA. 
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Chapter 2: Internalization and cellular distribution of doxorubicin and hyaluronic acid 
 
2.1 Materials: 
 
The 4′, 6-Diamidino-2-phenylindole dihydrochloride (DAPI) stain was obtained from 
Fisher Scientific. CD44 monoclonal antibody (Hermes-1) was obtained from Thermo Fisher 
Scientific (Rockford). Poly-L-Lysine coated glass coverslips were obtained from BD 
Biosciences. Fisherfinest* Premium Plain Glass Microscope Slides (Size: 75 x 25mm) were 
obtained from Fisher Scientific. Doxorubicin was obtained from Bedford Laboratories. CY7 NHS 
ester dye was obtained from Lumiprobe. DMEM was obtained from Lonza. Hyaluronic acid was 
obtained from Lifecore Biomedical. Lysotracker blue was obtained from Invitrogen.  
2.2 Method: 
 
Cell line and cell culture conditions: 
The cell line used was a human head and neck squamous cell carcinoma cell line, MDA-
1986. Cells were grown in 75-cm² cell culture flasks in DMEM with 10 % fetal bovine serum 
(FBS) and 1% L-glutamine. When a confluent state was reached, cells were seeded in 12-
multiwell plates (100,000-200,000 cells/well). Before imaging the cells, they were washed three 
times with phosphate buffer saline (PBS). Then, the coverslips were fixed on glass microscope 
slides. 
Cellular uptake and trafficking experiments: 
Doxorubicin has an excitation and an emission wavelength of 480 nm and 560 nm, 
respectively. HA does not have intrinsic fluorescence, i.e. it is non-fluorophorescent, so we 
conjugated HA to a laser dye CY7. CY7 dye has an excitation and an emission wavelength of 
750 nm and 773 nm, respectively. Thus, the fluorescence signals of doxorubicin and HA-CY7 
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could be captured simultaneously using YFP and CY7 filter sets, respectively. We used the dual 
labeled molecules HA-DOX-CY7 to localize the carrier (HA) and the drug (doxorubicin) at the 
same time. DAPI staining was used to stain the nucleus, which has an absorption maximum at a 
wavelength of 358 nm and emission maximum at 461 nm (13). Lysotracker blue was used to 
stain the lysosomes, which has an absorption maximum at a wavelength of 373 nm and an 
emission maximum at 422 nm. 
 
Figure 1: Fluorescence spectra of free DOX and free CY7 Dye. 
The uptake of the HA-DOX, HA-CY7 and DOX-HA-CY7 was monitored with an inverted 
fluorescence microscope at 15 minutes, 1, 6, 24 and 48 hours. Furthermore, the cell nuclei were 
stained with DAPI staining (7.5 µg/ml) and the cells were imaged after 6 hours. To explore if the 
lysosomes are the major degradation pathway of the nanoconjugates and the carries, the 
lysosomes were stained with lysotracker blue (150-nM) and co-incubated with free doxorubicin, 
HA-DOX, HA-CY7 or HA-DOX-CY7 for one hour.  
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Table 1: The concentration used for each drug in cell trafficking experiments as follows:  
Drugs Concentration (µg/mL) 
Doxorubicin 2 
HA-DOX 1.4 
HA-CY7 200 on HA basis 
HA-DOX-CY7 50 on HA basis 
 
Mechanism of cellular uptake: 
To explore the internalization mechanism of the HA-DOX and trafficking across the 
plasma cell membrane, we studied four different inhibition conditions. 
Table 2: Blocking conditions and uptake pathways. 
Pathway Inhibitor Mechanism 
HA receptor 
pathway 
Hermes-1 
(10 µg/mL) 
Inhibits CD44-mediated uptake  
HA receptor 
pathway 
Excess HA 
(5 and 10 mg/mL) 
Competitively inhibits HA  uptake 
Endocytosis Chlorpromazine 
(25-µM) 
Inhibits endocytosis by clathrin pathway 
Endocytosis 4°C Blocks energy-dependent internalization 
mechanisms (i.e. non-diffusion processes) 
 
In chlorpromazine and Hermes-1 experiments, cells were incubated for 30 minutes with 
each inhibitor alone and then co-incubated with HA-DOX, free doxorubicin, HA-CY7 or HA-
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DOX-CY7 for 1 hour. However, in HA competition experiments, cells were incubated with 
excess HA for 24 hours and then were incubated with HA-DOX, HA-CY7 or HA-DOX-CY7 for 
the 15 minutes, 1, 6, 24 and 48 hour time points. For 4°C experiments, cells were incubated for 
30 minutes and then treated with HA-DOX, free DOX or HA-DOX-CY7 for one hour. 
The fluorescence intensities for all four inhibition conditions were compared with non-
treated cells using Image J program with this equation:  
Corrected Total Cell Fluorescence (CTCF) = Integrated Density – (Area of selected cell x Mean 
fluorescence of background readings). Each assay was performed in triplicate or more and the 
statistical analysis was performed using student T test.  
Table 3: concentration of each drug used in inhibition and competition experiments: 
Drugs Concentration (µg/mL) 
Doxorubicin 2 
HA-DOX 1.4 
HA-CY7 400 on HA basis 
HA-DOX-CY7 50 on HA basis 
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2.3 Synthesis of HA-DOX conjugates: 
 
HA was conjugated to adipic acid dihydrazide (ADH) to facilitate the conjugation of HA to 
doxorubicin. HA (200 mg) with a molecular weight of 35 kDa was dissolved in 40 ml of ddH2O 
with 436 mg of adipic acid dihydrazide and 48 mg of 1-ethyl-3-[3-(dimethylamino)-
propyl]carbodiimide (EDCI). The pH was adjusted with 1-N HCl, and after 10 minutes the 
reaction was quenched with 0.1-N NaOH to reach pH 7. The solution was dialyzed for two days 
against ddH2O. Then, the solution was lyophilized after filtering (0.2-μm polysulfone membrane, 
Millipore). By using the ratio of ADH methylene protons to HA acetyl methyl protons, the degree 
of substitution was determined by ˡH-NMR in D2O. 
To conjugate DOX to HA, we allowed the ketone of DOX and the hydrazide side chain of 
HA–ADH to react and form a hydrazone. Briefly, 30 ml of 2-mM sodium phosphate buffer (pH 
6.5) was used to dissolve 110 mg of HA-ADH. DOX·HCl (2 mL, 2 mg/mL) was added drop wise 
to 25 mL of H2O. After adjusting the solution pH to 6.5 with 0.1-N NaOH, the solution was 
dialyzed against 2-mM sodium phosphate buffer (pH 7.8) until no further color change occurred. 
UV/Vis spectrophotometry at 480 nm was used to determine the degree of conjugation with a 
standard calibration curve (1–100 μg/mL). Also, gel permeation chromatography was used to 
confirm the conjugation by equivalent elution time (GPC; Shodex HQ-806 M column, 0.8 mL/min 
20-mM HEPES, pH 7.2) with refractive index and fluorescence detection (ex/em 480/590 nm) 
(10, 11, 12). 
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Figure 2: Synthesis of hyaluronan–doxorubicin (HA–ADH-DOX) conjugates              
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    Figure 3: Chemical structures of: A) CY7 NHS ester and B) HA-ADH-CY7. 
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2.4  Results: 
 
Intracellular Trafficking: 
Free doxorubicin was rapidly up taken by cells, and it was mainly localized in the cell 
nucleus (figure 4). HA-CY7 and free CY7 mainly localized in the cytosol (figure 6 and 7). HA-
DOX was found to be localized in two regions: in the nucleus and cytosol. After 15 minutes 
incubation, there was minimal internalization of HA-DOX. After 1 hour, there were two 
populations of cells. The majority of the cells with HA-DOX localized in the cytosol, and the 
other group of cells with HA-DOX localized in the nucleus. After 6 hours, HA-DOX mainly 
localized in the cell nucleus and remained there for 48 hours (figure 5). Also, HA-DOX-CY7 was 
found to be localized in two regions: the cytosol and cell nucleus. After 15 minutes, we could not 
distinguish between the doxorubicin signal and CY7 signal. After 1 hour to 48 hours, doxorubicin 
signal was found mainly in the cell nucleus, but CY7 signal was found in the cytosol.  At 48 
hours, there was a substantial amount of conjugates distribution in the cytoplasm where HA was 
bound to doxorubicin, suggesting that the HA-DOX conjugate released doxorubicin for an 
extended period of time (figure 8). The higher fluorescence intensity of free doxorubicin was 
found after incubating the cells with doxorubicin for 6 hours. Cells incubated with HA-DOX had 
higher fluorescence intensity after 24 hours. The difference between DOX and HA-DOX uptake 
was the earlier uptake of the free DOX compared to HA-DOX. Cells incubated with HA-CY7 had 
higher intensity after 24 hours while cells incubated with free CY7 had higher fluorescence 
intensity after 1 hour. The doxorubicin signal of the HA-DOX-CY7 was found the highest after 6 
hours, while the CY7 signal was found the highest after 1 hour incubation. 
To further confirm the localization of the drug in the nucleus, we stained the nucleus with 
DAPI stain. We found both the CY7 signals of HA-CY7 and the dual labeled molecule HA-DOX-
CY7 were localized in the cytosol. In contrast, the DOX signals of free DOX, HA-DOX and HA-
DOX-CY7 were found in the cell nucleus co-localized with the DAPI stain (figure 9). On the 
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other hand, lysosomes were found to be co-localized with free DOX, HA-DOX, HA-CY7, HA-
DOX-CY7 after one hour incubation with each molecule (figure 10). 
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            15 minute   1 hour 
              
6 hour                                                    24 hour           
                
48 hour 
 
Figure 4 :  
Fluorescence micrographs of free doxorubicin uptake at 15 minutes, 1, 6, 24 and 48 hours.  
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15  minute                            1 hour                                          1 hour 
                      
            6 hour                                   24 hour                                         24 hour       
                                    
                                                        48 hour 
                                                         
 
 
 
 
Figure 5 :  
Fluorescence micrographs of HA-DOX uptake at 15 minutes, 1, 6, 24, 48 hours.  
 
 
        
 
  
 
23 
 
 15 minute                                           1 hour 
               
 6 hour                                                24 hour 
                 
48 hour 
 
 
 
Figure 6:  
Fluorescence micrographs of HA-CY7 uptake at 15 minutes, 1, 6, 24 and 48 hours.  
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15 minute                                                 1 hour 
                
6 hour                                                       24 hour 
                 
 
48 hour 
 
 
Figure 7:  
Fluorescence micrographs of free CY7 uptake at 15 minutes, 1, 6, 24 and 48 hours.  
 
 
 
 
 
  
 
25 
 
15 minute                                      1 hour 
                 
 
6 hour                                            24 hour 
                 
48 hour 
 
Figure 8: 
Fluorescence micrographs of HA-DOX-CY7 uptake at 15 minute, 1, 6, 24 and 48 hours. 
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                                       DAPI                        DOX    signal                          Overlay 
             DOX       
                                  DAPI                                 DOX   signal                       Overlay 
        HA-DOX      
                                 DAPI                                  CY7   signal                      Overlay 
          HA-CY7        
                                DAPI                       DOX  signal         CY7   signal       Overlay 
 HA-DOX-CY7       
 
Figure 9:  
Fluorescence micrographs of HA-DOX, HA-CY7, free doxorubicin and HA-DOX-CY7 cell uptake 
at 6 hours. The nuclei were co-stained with DAPI (blue), DOX signal (red) and CY7 signal 
(green). 
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                                      DOX signal                       Lysotracker blue          Overlay 
                   DOX                        
               DOX SIGNAL                    Lysotracker blue                     Overlay 
               HA-DOX         
                                        CY7                               Lysotracker blue                  Overlay 
                 HA-CY7       
                                  DOX signal            Lysotracker Blue        CY7 signal        Overlay                  
  HA-DOX-CY7              
 
Figure 10:  
Fluorescence micrographs of free DOX, HA-DOX, HA-CY7 and HA-DOX-CY7 cell uptake at 1 
hours. The lysosomes were co-stained with lysotracker blue. 
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Mechanism of cellular uptake: 
  
HA-Doxorubicin and Free Doxorubicin: 
 The quantitative analysis of cells treated with HA-DOX and co-incubated under 
different inhibition conditions (excess HA, chlorpromazine and Hermes-1) showed a significant 
decrease in the fluorescence intensity, except cells pretreated with 5 mg/mL HA. Furthermore, 
the cells treated with 25-µM chlorpromazine had the lowest fluorescence intensity cells in the 
other treatment groups. The order of cell fluorescence intensities in all conditions were found as 
follows:  HA-DOX alone, excess HA,  Hermes-1 and chlorpromazine (Figure 18).  
 However, the quantitative analysis of cells treated with free doxorubicin showed a 
significant decrease in the fluorscence intensity only in cells pretreated with 25-µM 
chlorpromazine  (p value: 0.0018 figure 19). 
HA-CY7 and HA-DOX-CY7: 
 The quantitative analysis of cells treated with HA-CY7 and  co-incubated under 
different inhibition conditions (excess HA, chlorpromazine and Hermes-1) showed a significant 
decrease in the fluorescence intensity in all inhibition conditions. Furthermore, the cells treated 
with 25-µM chlorpromazine had the lowest fluorescence intensity compared to cells in the other 
treatment groups. The order of cell fluorescence intensities in all conditions was found as 
follows:  HA-CY7 alone, excess HA, Hermes-1, and chlorpromazine (Figure 20). However, the 
quantitative analysis of cells treated with HA-DOX-CY7 showed a significant decrease in the 
fluorscence intensity only in cells pretreated with 25-µM chlorpromazine  (p value less then 0.05 
figure 21). 
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Tempreture-dependent internalization studies:  
 As another way to inhibit the endocytosis process we compared the cellular uptake 
of HA-DOX, free DOX and HA-DOX-CY7  at  37°C and 4°C. We found that the cellular uptake of 
HA-DOX, free DOX and HA-DOX-CY7  significantly decreased at 4 °C compared to 37 °C 
(figure 22). 
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            DOX                                                                    HA-DOX                                                                            
                                                                                                             
 
          HA-CY7                                                             HA-DOX-CY7                                                                        
                                                                
 
Figure 11:  
Fluorescence micrographs of DOX, HA-DOX, HA-CY7 and HA-DOX-CY7  pretreated with 
Hermes1 for 30 minutes. 
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                      DOX                                                                  HA-DOX                                                        
                                                                       
 
                     HA-CY7                                                        HA-DOX-CY7                                       
                                            
                                                
 
 
 
Figure 12:  
Fluorescence micrographs of HA-DOX, HA-CY7 and HA-DOX-CY7 pretreated with 
chlorpromazine for 30 minutes. 
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15 minute                                            1 hour 
           
6 hour                                                 24 hour 
            
48 hour 
 
 
Figure 13:  
HA-DOX fluorescence micrographs of cells pretreated with 5 mg/mL HA for 24 hours. 
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      15 minute                                                          1 hour 
                                                                  
                  
      6 hour                                                                24 hour 
                              
      48 hour 
      
 
Figure 14:  
Free Dox fluorescence micrograph of cells pretreated with 5 mg/mL HA for 24 hours. 
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15 minute                                           1 hour 
                        
6 hour                                     24 hour                             
           
48 hour 
 
Figure 15:  
HA-CY7 fluorescence micrograph of cells pretreated with 5 mg/mL HA for 24 hours. 
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15 minute                                               1 hour 
           
6 hour                                                     24 hour 
             
  48 hour 
 
 
 
Figure 16:  
Free CY7 fluorescence micrograph of cells pretreated with 5 mg/mL HA for 24 hours. 
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  15 minute                                                    1 hour 
                            
6 hour                                                            24 hour 
                             
     48 hour 
 
Figure 17:  
HA-DOX-CY7 fluorescence micrograph of cells pretreated with 5 mg/mL HA for 24 hours. 
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Treatment P value 
Non-treated vs. Hermes 1 0.0023 
Non-treated vs. Chlorpromazine 0.0003 
Non-treated vs. 5 mg/mL HA 0.4049 
Non-treated vs. 10 mg/mL HA 0.0276 
 
 
Figure 18:  
Comparison of  cellular fluorescence intensity after one hour incubation with HA-DOX . 
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Treatment P value 
Non-treated vs. Hermes 1 0.4001 
Non-treated vs. Chlorpromazine 0.0018 
Non-treated vs. 5 mg/mL HA 0.6585 
Non-treated vs. 10 mg/mL HA 0.9993 
 
 
 
Figure 19:  
Comparison of the cellular fluorescence intensity after one hour incubation with doxorubicin. 
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Treatment P value 
Non-treated vs. Hermes 1 0.0047 
Non-treated vs. Chlorpromazine 0.0033 
Non-treated vs. 5 mg/mL HA 0.0325 
Non-treated vs. 10 mg/mL HA 0.0011 
 
 
 
Figure 20: 
Comparison of the cells fluorescence intensity after one hour incubation with HA-CY7.  
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Figure 21: 
Comparison of the cells fluorescence intensity after one hour incubation with  HA-DOX-CY7  
Cells treated with chlorpromazine had significant decrease of HA-DOX-CY7 uptake  
(p value: < 0.05) 
* CY7 signal 
* DOX signal 
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Figure 22: 
Comparison of the cellular fluorescence intensity after one hour incubation with  HA-DOX, DOX 
and HA-DOX-CY7 at 37°C and 4°C (p value less than 0.05 for all groups). 
N=3,20-30 cells/N 
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2.5 Discussion: 
 
 We found that the uptake of HA-DOX and HA-CY7 conjugates  was significantly 
decreased by the anti-CD44 antibody, Hermes-1, as well as by the presence of an excess of 
HA, suggesting that these conjugates enter the cell by a receptor-mediated process. CD44 is 
the primary cell surface receptor for HA, and it binds HA with five times greater affinity than the 
RHAMM (18). Excess HA also decreased the conjugates uptake, but the degree of inhibition 
was less than that by Hermes-1. This could be due to the more effective blocking by the 
monoclonal antibody Hermes-1. On the other hand, we cannot rule out the contribution of other 
HA receptors such as  RHAMM in the HA-DOX conjugates uptake. RHAMM also has the 
capability to bind HA, although cell surface CD44 function is dominant (19). Also, DOX  may 
have an effect on the cellular uptake of HA because the degree of the inhibtion of HA-DOX 
uptake was less than that in HA-CY7. 
 Endocytosis is one of the basic cellular processes that is used by all cell types to 
internalize  molecules by utilizing two different specialized proteins: clathrin and caveolin (20). 
Chlorpromazine, a specific inhibitor of clathrin-dependent endocytosis, significantly decreased 
the uptake of HA-DOX and HA-CY7 conjugates. These results suggest that HA-DOX  and HA-
CY7 conjugates are mainly internalized by the clathrin-mediated endocytosis pathway. Also, 
tempreture-dependence study showed that the uptake of HA-DOX conjugates was significantly 
decreased at 4 °C, which further confirmed the endocytic pathway and that his entry is energy 
dependent. 
 On the other hand, the degradation pathway of NPs following internalization is 
another important aspect of intracellular NP dynamics. Degradation by lysosome is a common 
terminal destination for the endocytic pathway (21). We found that the lysosomes and HA-DOX 
conjugates were  colocalized in the cytoplasm after 1 hour, suggesting that vesicles containing 
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the conjugates were migrated and fused with the lysosomes  following the uptake. This result 
also further confirms the endocytic pathway of the conjugates in which the lysosomes is  a 
common terminal destination of the endocytic pathway (22,23). 
 However, doxorubicin is a small hydrophobic molecule that could be internalized by 
passive diffusion. We found in this study that the uptake and cellular distribution of the DOX was 
decreased by chlorpromazine, a specific inhibitor of clathrin-dependent endocytosis, and by a 
temperature of 4°C. It has been suggested that the decrease in uptake of the DOX at 4°C 
compared to 37°C is due to the increase in the level of self-association of DOX and aggregation 
at 4°C by the formation of π-interaction (22,23). Also, the decrease in the DOX cellular uptake 
by chlorpromazine suggests the endocytic pathway of DOX. The uptake mechanism of DOX is 
not fully understood and needs further investigations. 
  We hypothesize that the conjugation of DOX to HA changes the uptake 
mechanism of DOX from passive diffusion to receptor mediated endocytosis process. The 
endocytosis process increases the retention time of DOX inside the cells and extends the 
release time of DOX from the conjugates. 
2.6 Conclusion: 
 
The suggested internalization mechanism of HA-DOX conjugates is an active transport 
mechanism mediated mainly by the CD44 receptor through a clathrin-dependent endocytic 
pathway. From the localization study, HA-CY7 distribution is in the cytosol and the free 
doxorubicin distribution is in the nucleus. This suggests that HA could not enter the nucleus, and 
HA-DOX conjugates enter the cell then release doxorubicin intracellularly. Lysosomes 
colocalized with HA-CY7, free doxorubicin, HA-DOX and HA-DOX-CY7 conjugates, so 
lysosomes could be the major degradation pathway of HA-DOX conjugates.  
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Chapter 3: Internalization of Sulfated-HA-CY7 experiments  
 
  
                            
                         Figure 23: Chemical structure of Sulfated HA-ADH-CY7. 
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3.1 Method: 
 
Cell line and cell culture condition: 
 The cell line used was a human head and neck squamous cell carcinoma cell line, MDA-
1986. Cells were grown in 75-cm² cell culture flasks in DMEM with 10 % fetal bovine serum 
(FBS) and 1% glutamine. When a confluent state was reached, cells were seeded in 12-
multiwell plates (100,000-200,000 cells/well). Before imaging the cells, they were washed three 
times with phosphate buffer saline (PBS). Then, the coverslips were fixed on glass microscope 
slides. 
Uptake and cells tracking experiments: 
The uptake of the sulfated HA was monitored by an inverted fluorescence microscope at 
1 hour. To explore the mechanism of the sulfated-HA uptake and trafficking across the plasma 
membrane, we studied three different inhibition conditions. 
Pathway Inhibitor Mechanism 
HA receptor pathway Hermes-1 
(10 µg/mL) 
Inhibits CD44-mediated uptake 
HA receptor pathway Excess HA 
(5 and 10 mg/mL) 
Competitively inhibits HA  uptake 
Endocytosis Chlorpromazine 
(25-µM) 
Inhibits endocytosis by clathrin pathway 
 
In chlorpromazine and Hermes-1 experiments, cells were incubated for 30 minutes with 
each inhibitor alone, and then co-incubated with Sulfated-HA-CY7 for 1 hour. In HA competition 
experiments, cells were treated with 10 mg/mL HA for 24 hours, and then co-incubated with 
sulfated HA for 1 hour. The fluorescence intensities for all three inhibition conditions were 
compared with non-treated cells using Image J program with this equation:  
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Corrected Total Cell Fluorescence (CTCF) = Integrated Density – (Area of selected cell 
X Mean fluorescence of background readings). Each assay was performed in triplicate and the 
statistical analysis was performed using student T test.   
3.2 The results: 
 
Sulfated HA-Cy7 has similar cellular distribution as the parent HA-CY7, and it is mainly localize 
in the cytosol (figure 24) 
                                     1 h  
                                 non treated 
                             
1 h                                                      1 h 
Treated with Hermes-1                      Treated with chlorpromazine 
                                
                  
1 h                                                         1 h 
Treated with 5 mg/mL HA                  Treated with 10 mg/mL HA 
                   
                                 
Figure 24: 
Fluorescence micrographs of Sulfated-HA-CY7 (1 hour). 
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Figure 25: Comparison of the cellular fluorescence intensity after one hour incubation with  
Sulfated HA-CY7 
N=3,20-30 cells/N 
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3.3 Discussion: 
 
Hyaluronan was functionalized with a carboxylic functional group. We utilized this 
carboxylic functional group to conjugate HA to doxorubicin. However, this conjugation 
decreased the solubility of HA conjugates in the aqueous solution. Our lab derivitized the parent 
HA with a sulfate group to increase the solubility of the HA. In this work, we also compared the 
uptake of this sulfated form of HA to the parent HA. Sulfated HA can pass the cellular 
membrane, and it is mainly localized and distributed in the cytosol (figure 24). There is no effect 
of Hermes-1, chlorpromazine or excess HA on the uptake of the sulfated HA (figure 25). These 
results suggest that the uptake of sulfated HA is not dependent on the CD44 pathway, and the 
uptake could be by another mechanism such as passive diffusion or non-clathrin-mediated 
endocytosis. 
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Chapter 4: 
Future work: 
 
To explore the exact mechanism of the cellular uptake of HA-DOX and HA, we could try 
several blocking conditions such as: inhibiting energy dependent endocytosis processes; 
inhibiting ATP production; inhibiting caveoline-mediated endocytosis; inhibiting clathrin and 
caveolin-independent endocytosis pathways, macropinocytosis, and phagocytosis. Also, we 
could inhibit ATP production by incubating the cells with sodium azide 100-mM for 30 minutes 
before co-incubation of the cells with the nanoparticles. We could use metabolic inhibitors to 
inhibit the endocytosis such as colchicine (15-mM). Furthermore, we could specifically inhibit the 
caveoline-mediated endocytosis by incubating the cells with 1.25 µg/mL filipin for 30 minutes. 
Macropinocytosis is an actin-dependent endocytic mechanism mainly used by cells to 
internalize large amounts of fluids and growth factors. In contrast, phagocytosis is an endocytic 
mechanism used by cells to internalize solid particles, and it is also an actin-dependent process. 
To exclude the phagocytosis pathways we could try Vibrant™ Phagocytosis assay kit.  We may 
not study the macro pinocytosis pathway because it involves internalization of relatively large 
particles (1–5 µm diameter), much larger than the HA-DOX conjugates (3). 
We also could try different HA receptors blockers such as CD168 antibody to observe if 
they are involved in the uptake mechanism. Increasing the concentration of Hermes-1, 
chlorpromazine and HA in competitive experiment is another way to determine if the uptake is 
completely inhibited and if these mechanisms play a dominant role in HA-DOX uptake. 
 
 
 
 
  
 
50 
 
References: 
1. Hillery, A., Lloyd, A., & Swarbrick, J. (Eds.) (2001). Drug Delivery and Targeting. Boca 
Raton: Taylor and Francis. 
2. De Jong, W.H. & Borm, P.J. (2008). Drug delivery and nanoparticles: applications and 
hazards. Int. J. Nanomedicine, 3, 133-149. 
3. Contreras-Ruiz, L., de la Fuente, M., Párraga, J., López-García, A., Fernández, I., Seijo, 
B., Sánchez, A., Calonge, M., Diebold., Y.(2011). Intracellular trafficking of hyaluronic 
acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. Mol. 
Vis, 17,279-90.  
4. Frasher, J.R.E et al, Laurent, T. C., Laurent, U. B. G. (1997)                                                                           
Hyaluronan: its nature, distribution, functions and turnover. Journal of Internal Medicine, 
242 (1), 27–33. 
5. Ouhtit, A., Abd Elmageed, Z., Abdraboh, M., Lioe, T., Raj, M. (2007).In vivo evidence for 
the role of CD44s in promoting breast cancer metastasis to the liver. Am. J. Path. 
171,2033-2039. 
6. Edetsberger, M., Gaubitzer, E., Valic, E., Waigmann, E., Köhler, G. (2005). Detection of 
nanometer-sized particles in living cells using modern fluorescence fluctuation methods. 
Biochem Biophys Res Commun., 332,109–16. 
7. Shenoy, D., Fu, W., Li, J., Crasto, C., Jones,G., DiMarzio,C., Sridhar,S.,  Amiji, M. 
(2006). Surface functionalization of gold nanoparticles using hetero-bifunctional poly 
(ethylene glycol) spacer for intracellular tracking and delivery. Int. J. Nanomedicine, 1, 
51–7. 
8. Panyam, J., Zhou, W.Z., Prabha, S., Sahoo, S., Labhasetwar, V. (2002).Rapid endo-
lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug 
and gene delivery. FASEB. J., 16, 1217–26. 
  
 
51 
 
9. Konan, Y.N., Chevallier, J., Gurny, R., Allémann, E.  (2003).Encapsulation of p-THPP 
into nanoparticles: cellular uptake, subcellular localization and effect of serum on 
photodynamic activity. Photochem. Photobiol., 77,638–44. 
10.  Cai, S., Thati, S., Bagby, T., Diab, H., Davies, N., Cohen, M., & Forrest, L. 
(2010).Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves. J.  
Control. Rel, 146, 212–218. 
11.  Luo, Y., Prestwich, G.D.  (1999).Synthesis and selective cytotoxicity of a hyaluronic acid 
antitumor bioconjugate, Bioconjug. Chem., 10 (5), 755–763. 
12. Bouhadir, K.H., Alsberg, E., Mooney, D.J. (2001). Hydrogels for    combination delivery 
of antineoplastic agents, Biomaterials, 22 (19) 2625–2633. 
13.  Cai. S. (2010). Internalization of Nanocarriers into Tumor Cells. Unpublished doctoral 
dissertation, University of Kansas. 
14. Sugahara, S., Okuno, S., Yano, T., Hamana, H., Inoue, K. (2001).Characteristics of 
tissuedistribution of various polysaccharides as drug carriers: influences of 
molecularweight and anionic charge on tumor targeting, Biol. Pharm. Bull. 24 (5) 535–
543. 
15.   Cera, C., Palumbo, M., Stefanelli, S., Rassu, M., Palù, G. (1992). Water-soluble 
polysaccharideanthracycline conjugates: biological activity, Anticancer Drug Des. 7 (2) 
143–151. 
16.  Akima, K., Ito. H., Iwata, Y., Matsuo, K., Watari, N., Yanagi, M., Hagi, H., Oshima, K., 
Yagita, A., Atomi, Y., Tatekawa, I. (1996). Evaluation of antitumor activities of 
hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity, 
J. Drug Target. 4 (1) 1–8. 
17.   Takemura, G., Fujiwara, H. (2007). Doxorubicin-induced cardiomyopathy from   the 
cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis. 49 (5) 330–352. 
  
 
52 
 
18.  Sherman, L., Sleeman, J., Herrlich, P., Ponta, H. (1994). Hyaluronate receptors: key 
players in growth, differentiation, migration and tumor progression. Curr. Opin. Cell. Biol; 
6:726-33. 
19.  Nedvetzki, S., Gonen, E., Assayag, N., Reich, R., Williams, RO., Thurmond, RL., 
Huang, JF., Neudecker, BA., Wang, FS., Turley, EA., Naor, D. (2004). RHAMM, a 
receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-
knockout mice: a different interpretation of redundancy. Proc. Natl. Acad. Sci. USA; 
101:18081-6. 
20.  Mayor, S., Pagano, RE. (2007).  Pathways of clathrin-independent endocytosis. Nat. 
Rev. Mol. Cell Biol.; 8:603-12. 
21.  Van ME, Klumperman, J. (2008). Imaging and imagination: understanding the endo-
lysosomal system. Histochem. Cell. Biol; 129:253-66. 
22.   Dalmark, M., Storm, H. (1981). A Fickian diffusion process with features of transport 
catalysis. Doxorubicin transport in Human red blood cells. J. Gen. Physiol, 78,349-364. 
23.  Majumdar, S., Kobayashi, N., Krise, JP., Siahaan, TJ. (2007). Mechanism of 
internalization of an ICAM-1-derived peptide by human leukemic cell line HL-60: 
influence of physicochemical properties on targeted drug delivery. Mol. Pharm., Sep-
Oct; 4(5):749-58. 
